Thu, Apr 17, 2014, 10:06 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

ries123 8 posts  |  Last Activity: Mar 26, 2014 10:25 AM Member since: Jun 26, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    I am holding on to my $17.50 SHORT order

    by booyahbest Mar 26, 2014 10:11 AM
    ries123 ries123 Mar 26, 2014 10:25 AM Flag

    The only thing which drops is your undies when they are full of your bllsht

    Sentiment: Strong Buy

  • after selling pre-market at the 12 bucks level... closing green today !

    Sentiment: Strong Buy

  • Reply to

    How many Pre-Market shares.....

    by insmhistorian Mar 26, 2014 8:41 AM
    ries123 ries123 Mar 26, 2014 8:47 AM Flag

    2 million..

  • Reply to

    Can't sleep....

    by blank2thisone Mar 26, 2014 2:45 AM
    ries123 ries123 Mar 26, 2014 3:14 AM Flag

    Hey nerdrup, if you can't think of a reply yourself do not use mine (topic: After hours going up).. Leave or stay and get roasted !

    Sentiment: Strong Buy

  • Reply to

    Can't sleep....

    by blank2thisone Mar 26, 2014 2:45 AM
    ries123 ries123 Mar 26, 2014 2:57 AM Flag

    Goosebumps, nail-biting, cardiac arrythmia, sweaty feet, cold fingers... need to serve myself first !

    Good luck to all longs !

    Sentiment: Strong Buy

  • Why is it all of a sudden ARIKAYCE..?

  • ries123 by ries123 Feb 19, 2014 7:05 AM Flag

    Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

    Initial 12-Month Data Demonstrate Long-Term Safety and Durability of Effect

    MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq GS:INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, provides an interim update from the Company's CLEAR-110 study, an ongoing, two-year, open-label extension study of once-daily ARIKACE®, or liposomal amikacin for inhalation, to treat Pseudomonas aeruginosa (Pa) in cystic fibrosis (CF) patients. These data are from 98 patients who have completed the first 12 months (six cycles) of the CLEAR-110 extension study. The data were collected as part of a scheduled data safety monitoring board (DSMB) review of the CLEAR-110 extension study. The data showed that ARIKACE was well tolerated, and there was a sustained improvement from baseline level in Forced Expiratory Volume in One Second (FEV1). These patients also experienced a sustained reduction in density of Pa sputum while on treatment.

    Sentiment: Strong Buy

  • ries123 by ries123 Feb 11, 2014 8:17 AM Flag

    On February 10, 2014, Insmed Incorporated (the “Company”) entered into a Contract Manufacturing Agreement (the “Agreement”) with Therapure Biopharma Inc. (“Therapure”) for the manufacture of the Company’s product ARIKACE TM , liposomal amikacin for inhalation, (“Arikace”). Pursuant to the Agreement, the Company and Therapure will collaborate to construct a production and quality control area for the manufacture and testing of Arikace in Therapure’s existing manufacturing facility in Mississauga, Ontario, Canada. Therapure will manufacture Arikace for the Company on a non-exclusive basis.

    Sentiment: Strong Buy

13.41+0.88(+7.02%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT
Advanced Micro Devices, Inc.
NYSEThu, Apr 17, 2014 4:00 PM EDT